Drug intelligence / Profile preview

Acunol

Development stage: Unknown
Lead developer: Plymouth Healthcare Products
Modality: Small Molecules
Administration: Oral

Overview

Acunol is a biochemical homeopathic oral medication marketed by Plymouth Healthcare Products for the treatment of various inflammatory skin conditions. It is formulated as a 600 mg scored tablet containing a combination of potassium bromide, sodium bromide, zinc sulfate, sulfur, and nickel sulfate. The product is indicated for the treatment of mild to moderate acne vulgaris, acne rosacea, peri-oral dermatitis, and folliculitis. While its exact mechanism of action is not fully understood, it is hypothesized that the bromide components may enhance the immune response by increasing the phagocytic and bactericidal activity of neutrophils. Acunol has been available as a prescription homeopathic drug since 2006, though it remains classified as an unapproved product by the FDA.

Brand names: Acunol

Beyond the preview

Go deeper on Acunol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acunol.

Explore the full profile